Meeting
2015 Gastrointestinal Cancers Symposium
A randomized, open-label, phase I/II trial of gemcitabine plus nab-paclitaxel with or without FG-3019 as neoadjuvant chemotherapy in locally advanced, unresectable pancreatic cancer.
Authors
Flavio G. Rocha
Virginia Mason Medical Center, Seattle, WA
Flavio G. Rocha , Scott Helton , Vincent J. Picozzi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT02210559
Citation
J Clin Oncol 33, 2015 (suppl 3; abstr TPS500)
DOI
10.1200/jco.2015.33.3_suppl.tps500
Abstract #
TPS500
Poster Bd #
F15
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
Randomized, open-label trial of gemcitabine/nab-paclitaxel (G/NP) ± pamrevlumab (P) as neoadjuvant chemotherapy in locally advanced, unresectable pancreatic cancer (LAPC).
First Author: Vincent J. Picozzi
Poster
2016 Gastrointestinal Cancers Symposium
Randomized, open-label trial of gemcitabine/nab-paclitaxel (G/NP) ±FG-3019 as neoadjuvant chemotherapy in locally advanced, unresectable pancreatic cancer (LAPC).
First Author: Vincent J. Picozzi
Poster
2020 ASCO Virtual Scientific Program
NAPOLI-3: An open-label, randomized, phase III study of first-line liposomal irinotecan + 5‑fluorouracil/leucovorin + oxaliplatin versus nab-paclitaxel + gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma.
First Author: Zev A. Wainberg
